ArticleJournal of visualized experiments : JoVE2015
Porous silicon microparticles for delivery of siRNA therapeutics.
Article in Journal of visualized experiments : JoVE, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The advancement of siRNA-based nanomedicine for tumor therapy.Nanomedicine (London, England) · 2024Review
- Extracellular vesicles as personalized medicine.Molecular aspects of medicine · 2023Review
- Unraveling multilayered extracellular vesicles: Speculation on cause.Journal of extracellular vesicles · 2023Article
- Extracellular vesicle therapeutics from plasma and adipose tissue.Nano today · 2021Article
- A Simple and Quick Method for Loading Proteins in Extracellular Vesicles.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics.Theranostics · 2020Review
- Lipoprotein-based drug delivery.Advanced drug delivery reviews · 2020Review
- Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles.Acta biomaterialia · 2019Article
- Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.Biomedical microdevices · 2019Review
- Clinical Cancer Nanomedicine.Nano today · 2019Article
- Extracellular vesicle-based drug delivery systems for cancer treatment.Theranostics · 2019Review
- Chloroquine and nanoparticle drug delivery: A promising combination.Pharmacology & therapeutics · 2018Review
- Trends towards Biomimicry in Theranostics.Nanomaterials (Basel, Switzerland) · 2018Review
- A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery.Scientific reports · 2017Article
- Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.Cancer letters · 2017Article
- Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Journal of materials chemistry. B · 2017Article
- Enzyme-responsive multistage vector for drug delivery to tumor tissue.Pharmacological research · 2016Article
- A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Pharmacological research · 2016Article
- Hesperetin Liposomes for Cancer Therapy.Current drug delivery · 2016Article
- Multistage vector (MSV) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small interfering RNA (siRNA) can be used to suppress gene expression, thereby providing a new avenue for the treatment of various diseases. However, the successful implementation of siRNA therapy requires the use of delivery platforms that can overcome the major challenges of siRNA delivery, such as enzymatic degradation, low intracellular uptake and lysosomal entrapment. Here, a protocol for the preparation and use of a biocompatible and effective siRNA delivery system is presented. This platform consists of polyethylenimine (PEI) and arginine (Arg)-grafted porous silicon microparticles, which can be loaded with siRNA by performing a simple mixing step. The silicon particles are gradually degraded over time, thereby triggering the formation of Arg-PEI/siRNA nanoparticles. This delivery vehicle provides a means for protecting and internalizing siRNA, without causing cytotoxicity. The major steps of polycation functionalization, particle characterization, and siRNA loading are outlined in detail. In addition, the procedures for determining particle uptake, cytotoxicity, and transfection efficacy are also described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.